Inaba M, Tashiro T, Kobayashi T, Sakurai Y, Maruo K, Ohnishi Y, Ueyama Y, Nomura T
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo.
Jpn J Cancer Res. 1988 Apr;79(4):517-22. doi: 10.1111/j.1349-7006.1988.tb01621.x.
To reproduce clinical effects of various antitumor agents in the human tumor/nude mouse model, we investigated the responsiveness of 11 lines of human gastric tumor xenografts to doses of the agents pharmacokinetically equivalent to the respective clinical doses, which we designated the "rational dose" (RD). We found that the response rates to mitomycin C, 3-[(4-amino-2-methyl-5-pyrimidinyl]methyl-1-[2-chloroethyl]-1- nitrosourea (ACNU), adriamycin, 5-fluorouracil were 18%, and that to vinblastine was 30%; on the other hand, those to vincristine, methotrexate, and cyclophosphamide were poor. In contrast, in our previous study using the maximum tolerated doses, response rates to mitomycin C, ACNU, and vinblastine were as high as 64-82%, and those to adriamycin and 5-fluorouracil were 18%. When these results were compared with the clinical response rates of gastric tumors, as a whole, the results with RD's exhibited much better coincidence with the clinical data in terms of relative therapeutic potency, indicating the validity of the use of clinically equivalent doses instead of maximum tolerated doses in the human tumor model.
为了在人肿瘤/裸鼠模型中重现各种抗肿瘤药物的临床效果,我们研究了11株人胃癌异种移植瘤对药物剂量的反应性,这些剂量在药代动力学上等同于各自的临床剂量,我们将其称为“合理剂量”(RD)。我们发现,丝裂霉素C、3-[(4-氨基-2-甲基-5-嘧啶基)甲基]-1-(2-氯乙基)-1-亚硝基脲(ACNU)、阿霉素、5-氟尿嘧啶的反应率为18%,长春碱的反应率为30%;另一方面,长春新碱、甲氨蝶呤和环磷酰胺的反应率较低。相比之下,在我们之前使用最大耐受剂量的研究中,丝裂霉素C、ACNU和长春碱的反应率高达64%-82%,阿霉素和5-氟尿嘧啶的反应率为18%。当将这些结果与胃癌的临床反应率进行比较时,总体而言,RD结果在相对治疗效力方面与临床数据的吻合度更高,表明在人肿瘤模型中使用临床等效剂量而非最大耐受剂量是有效的。